Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health,
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) and some of its officers, alleging violations of federal securities laws. The lawsuit claims Hims made false and misleading statements, including sharing consumer health information with third-party advertisers and charging for prescriptions before medical consultations. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case by November 1, 2026, as lead plaintiffs.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers
The Rosen Law Firm is encouraging investors of Hims & Hers Health, Inc. (NYSE: HIMS) to secure legal counsel before the November 2, 2026 deadline for a securities class action lawsuit. The lawsuit alleges that Hims & Hers made false and misleading statements, including sharing health information with third-party advertisers and charging for prescriptions before proper consultations. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, may be entitled to compensation.
Hims & Hers Health, Inc. (NYSE: HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that HIMS made materially false statements and failed to disclose that it shared consumer health information with third-party advertisers and charged for prescriptions before medical consultations, leading to regulatory scrutiny and a stock drop following an FTC lawsuit. Investors have until November 2, 2026, to seek lead plaintiff status.
1 MONTH INVESTOR DEADLINE: Hims & Hers Health, Inc.
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Hims & Hers Health, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff. The lawsuit claims Hims & Hers made false statements regarding sharing consumer health information, deceptive billing practices, and the resulting regulatory scrutiny.
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS
Hims & Hers Health (NYSE: HIMS) is facing a securities class action lawsuit following a federal complaint by the FTC, the State of Utah, and the County of Los Angeles. The lawsuit alleges Hims deceptively shared sensitive user medical data with third-party advertising platforms and violated ROSCA by enrolling consumers in recurring subscriptions without informed consent. This news led to a 14.7% drop in Hims' stock price, erasing over $970 million from its market capitalization.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging federal securities law violations. The lawsuit claims that Hims & Hers made materially false and misleading statements regarding its sharing of consumer health information with third-party advertisers and its prescription practices, which led to regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.
Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately Lead Plaintiff Deadline November 2, 2026
Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for allegedly making false and misleading statements to investors between August 4, 2025, and July 29, 2026. The lawsuit claims the company shared consumer health information with third parties, charged for prescriptions without clear consultation, and created obstacles to cancellations, leading to regulatory scrutiny from the FTC and California. Investors who suffered losses during this period are encouraged to contact Wolf Haldenstein by the lead plaintiff deadline of November 2, 2026.
HIMS ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before November 2, 2026 Deadline
Robbins Geller Rudman & Dowd LLP announces that investors who purchased Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that Hims & Hers made misleading statements and failed to disclose that it shared consumer health information with third-party advertisers and deceptively charged for prescriptions. This action follows a Federal Trade Commission lawsuit against Hims & Hers for similar practices, which caused the company's shares to decline by nearly 15%.
HIMS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Hims Inves
Faruqi & Faruqi, LLP is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) about a securities class action lawsuit deadline on November 2, 2026. The lawsuit alleges that Hims shared consumers' sensitive health information with third-party advertisers and misled customers about billing and cancellation practices, leading to a Federal Trade Commission lawsuit and a significant drop in stock price. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to contact the firm to discuss their options and potentially seek lead plaintiff status.
Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately Lead Plaintiff Deadline November 2, 2026
Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased shares between August 4, 2025, and July 29, 2026, and suffered losses. The lawsuit alleges that Hims & Hers made materially false and misleading statements, failed to disclose that it shared consumer health information with third-party advertising platforms, and charged for prescriptions before consultations. These actions led to a lawsuit by the FTC and California/Utah consumer protection divisions, causing a significant drop in Hims & Hers' stock price on July 29, 2026.
Robbins LLP Urges HIMS Stockholders to Contact the Firm for Information About the Hims & Hers Health, Inc. Class Action Lawsuit
Robbins LLP is urging stockholders of Hims & Hers Health, Inc. (NYSE: HIMS) to contact their firm regarding a class action lawsuit filed against the company. The lawsuit alleges that Hims & Hers shared customers' protected health information with advertising platforms and engaged in deceptive billing and cancellation practices. Investors who suffered losses between August 4, 2025, and July 29, 2026, are encouraged to reach out to Robbins LLP before the November 2, 2026, lead plaintiff deadline.
Robbins LLP Urges HIMS Stockholders to Contact the Firm for Information About the Hims & Hers Health, Inc. Class Action Lawsuit
Robbins LLP is urging Hims & Hers Health, Inc. (NYSE: HIMS) stockholders to contact the firm regarding a class action lawsuit. The lawsuit alleges that Hims & Hers shared customers' protected health information with advertising platforms and engaged in deceptive advertising practices. This follows an FTC lawsuit filed against Hims on July 29, 2026, which led to a significant drop in HIMS stock.
Deadline Alert: Hims & Hers Health, Inc. (HIMS)
Glancy Prongay Wolke & Rotter LLP is reminding investors of Hims & Hers Health, Inc. (HIMS) about an upcoming November 2, 2026 deadline to file a lead plaintiff motion in a securities fraud class action lawsuit. The lawsuit alleges that Hims made misleading statements and failed to disclose that it shared consumer health information with third-party advertisers and charged for prescriptions almost immediately, leading to regulatory scrutiny and a significant stock drop on July 29, 2026. Investors who suffered losses between August 4, 2025, and July 29, 2026, are urged to contact the law firm.
Hims & Hers Health (HIMS) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline
Hagens Berman has filed a securities class action lawsuit against Hims & Hers Health (HIMS) and certain executives, following a federal complaint by the FTC accusing the company of serious business misconduct. The lawsuit alleges that Hims misled investors by deceptively sharing health data and violating billing practices, leading to a significant stock drop on July 29, 2026. Investors who suffered substantial losses are encouraged to contact Hagens Berman before the November 2, 2026, lead plaintiff deadline.
INVESTOR ALERT: Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that HIMS made misleading statements and failed to disclose that it shared consumers' health information with third-party advertising platforms and charged for prescriptions before medical consultation, leading to regulatory scrutiny. Investors who suffered losses have until November 2, 2026, to seek lead plaintiff status.
Hims & Hers Health, Inc. (NYSE: HIMS) Class Action Lawsuit: Investors Face November 2, 2026, Deadline
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased shares between August 4, 2025, and July 29, 2026. The lawsuit alleges that HIMS made materially false statements and failed to disclose that it shared consumer health information with third-party advertisers and charged consumers for prescriptions prematurely, leading to regulatory scrutiny and a stock drop following an FTC lawsuit. Investors have until November 2, 2026, to seek lead plaintiff status.
Hims & Hers CFO Okupe sells $876,846 of HIMS stock
Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NASDAQ:HIMS), recently sold 29,277 shares of Class A Common Stock for $876,846 on September 22, 2026, under a Rule 10b5-1 trading plan. On the same day, Okupe also acquired 14,000 shares through vested stock options for $70,140. These transactions come as HIMS shares have shown significant volatility and are considered overvalued according to InvestingPro analysis, despite a 52% return over the past six months.
Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit
Hagens Berman Sobol Shapiro LLP announced a securities class action lawsuit against Hims & Hers Health, Inc. (HIMS) following a federal complaint from the FTC, the State of Utah, and the County of Los Angeles. The lawsuit alleges that Hims misled investors by deceptively sharing health data and violating the Restore Online Shoppers' Confidence Act with its subscription practices. Investors who suffered substantial losses are encouraged to come forward to lead the class action.
Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately
A class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased shares between August 4, 2025, and July 29, 2026, and suffered losses. The lawsuit alleges that Hims & Hers made materially false and misleading statements, including failing to disclose that it shared consumers' health information with third-party advertising platforms and charged for prescriptions almost immediately after intake forms were submitted. Investors are encouraged to contact Wolf Haldenstein Adler Freeman & Herz LLP by the lead plaintiff deadline of November 2, 2026.
Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately Lead Plaintiff Deadline November 2, 2026
Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased shares between August 4, 2025, and July 29, 2026, and suffered losses. The lawsuit alleges that Hims & Hers made materially false and misleading statements, including sharing consumer health information with third-party advertisers and charging for prescriptions almost immediately without proper consultation, leading to regulatory scrutiny from the FTC and state consumer protection agencies. Following the FTC's announcement on July 29, 2026, Hims & Hers stock dropped by 14.73%.
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
Rosen Law Firm is encouraging investors of Hims & Hers Health, Inc. (NYSE: HIMS) to secure legal counsel before the November 2, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Hims & Hers made materially false and misleading statements regarding the sharing of consumer health information, billing practices, and potential regulatory scrutiny, causing investors damages. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, may be entitled to compensation.
HIMS Stockholders Have Rights – If You Lost Money Investing
A class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers shared customers' protected health information with advertising platforms and engaged in deceptive billing practices, which led to a significant stock drop after the FTC announced a lawsuit against the company. Investors who suffered losses are encouraged to contact Robbins LLP by the November 2, 2026, lead plaintiff deadline.
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) who suffered substantial losses to file lead plaintiff applications by November 2, 2026. This class action lawsuit alleges that Hims & Hers Health failed to disclose material information regarding deceptive privacy and billing practices, which led to a 14.73% stock decline following a Federal Trade Commission (FTC) lawsuit announcement. Investors who purchased securities between August 4, 2025, and July 29, 2026, are encouraged to contact KSF for legal guidance.
HIMS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Hims made false and misleading statements by sharing consumers' health information with third-party advertising platforms, deceptively charging for prescriptions, and failing to disclose regulatory scrutiny, which led to a significant drop in its stock price after a Federal Trade Commission lawsuit was announced. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, and suffered losses are encouraged to contact the firm.
INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - HIMS
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, and suffered substantial losses, have until November 2, 2026, to seek appointment as lead plaintiff. The lawsuit claims Hims & Hers made misleading statements regarding sharing consumer health information, deceptive billing practices, and the resulting regulatory scrutiny from the Federal Trade Commission.
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
Hims & Hers Health (HIMS) shares dropped almost 7% due to increasing legal challenges, including an FTC lawsuit alleging privacy violations and deceptive billing, and a related securities class action. This comes alongside disappointing Q2 earnings that showed a wider net loss despite significant revenue growth. The company faces ongoing volatility and legal expenses, with its stock already down over 45% in the past year.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged federal securities law violations. The lawsuit covers investors who purchased Hims securities between August 4, 2025, and July 29, 2026, claiming the company made false statements and failed to disclose issues such as sharing consumer health information with third parties and improper billing practices. Investors have until November 1, 2026, to request to be appointed as lead plaintiff.
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS
ClaimsFiler is reminding investors who lost over $100,000 in Hims & Hers Health, Inc. (NYSE: HIMS) to file lead plaintiff applications by November 2, 2026, in a securities class action lawsuit. The lawsuit alleges that Hims & Hers and its executives failed to disclose material information, violating federal securities laws, specifically regarding the company's sharing of consumer health data and misleading billing practices. This alert follows a Federal Trade Commission lawsuit against the company, which caused a significant drop in Hims & Hers' stock price.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
Rosen Law Firm is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) who purchased securities between August 4, 2025, and July 29, 2026, about the upcoming lead plaintiff deadline of November 2, 2026, in a securities class action lawsuit. The lawsuit alleges that Hims & Hers made materially false and misleading statements by failing to disclose that it shared consumer health information with third-party advertisers, charged for prescriptions without prior consultation, and was likely to face regulatory scrutiny and penalties. Investors are encouraged to contact the firm to join the class action and learn about their rights.
Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, Inc. Investors of the Upcoming Lead Plaintiff Deadline and Urges Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for allegedly making false and misleading statements to investors. The lawsuit claims that Hims shared consumer health information with third-party advertisers, charged for prescriptions immediately without proper consultations, and is likely to incur regulatory fees and penalties. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply to be lead plaintiff.
HIMS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP is reminding investors of the November 2, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit against Hims & Hers Health, Inc. The lawsuit alleges that Hims made false and misleading statements by sharing consumers' health information with third-party advertisers and deceptively charging for prescriptions, leading to regulatory scrutiny and a stock price drop after the FTC filed a lawsuit. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to contact the firm to discuss their options.
Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investor
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who suffered losses between August 4, 2025, and July 29, 2026. The lawsuit follows a Federal Trade Commission (FTC) action alleging that Hims & Hers failed to clearly disclose prescription charges, made it difficult to cancel subscriptions, and misled consumers about privacy by sharing health information with third parties. Investors with significant losses are encouraged to seek a leadership role in the class action before the November 2, 2026 deadline.
Hims & Hers Health, Inc. (HIMS) Investors: November 2, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Hims & Hers Health, Inc. (HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that HIMS made materially false statements and failed to disclose deceptive privacy practices, leading to a stock drop after the FTC filed a lawsuit. Investors have until November 2, 2026, to file for lead plaintiff status.
Hims & Hers Health, Inc. Securities Fraud Class Action
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against Hims & Hers Health, Inc. (HIMS) for alleged deceptive privacy and billing practices, which led to a significant stock decline. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply for lead plaintiff status. The lawsuit follows a Federal Trade Commission (FTC) complaint against Hims for sharing sensitive health information and misleading billing practices.
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Hims & Hers Health, Inc. (HIMS). The lawsuit alleges that the company made misleading statements and failed to disclose critical information to investors, specifically regarding sharing consumer health data, charging practices, and potential regulatory scrutiny. Investors who suffered losses between August 4, 2025, and July 29, 2026, have until November 2, 2026, to move for lead plaintiff status.
HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER ALERT Bernstein
Bernstein Liebhard LLP has issued a shareholder alert for Hims & Hers Health, Inc. (HIMS) investors, reminding them of an upcoming November 2, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that Hims made false and misleading statements about its business operations and financial stability, causing investors to suffer losses. Investors who purchased HIMS shares between August 4, 2025, and July 29, 2026, are encouraged to join the lawsuit.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP is reminding investors of a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged securities fraud, stemming from the company's disclosure of customer health data to third-party advertising platforms and anticipated regulatory scrutiny. Shareholders who purchased HIMS shares between August 4, 2025, and July 29, 2026, are encouraged to contact the firm by November 2, 2026, to discuss lead plaintiff opportunities and potential recovery for their losses. The lawsuit claims Hims & Hers made false and misleading statements, causing investors damages when the truth emerged.
Kahn Swick & Foti, LLC Alerts Hims & Hers Health, Inc. (HIMS) Investors With Six-Figure Losses to Filing Deadline
Kahn Swick & Foti, LLC (KSF) has alerted investors of Hims & Hers Health, Inc. (HIMS) with substantial losses to a November 2, 2026 deadline to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Hims & Hers Health and its executives failed to disclose material information regarding the sharing of consumers' sensitive health information and deceptive billing practices, leading to a significant drop in stock price after the FTC filed a lawsuit. KSF encourages affected investors to contact them to discuss their legal rights and potential recovery.
Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action
Robbins LLP is urging stockholders of Hims & Hers Health, Inc. (NYSE: HIMS) who incurred losses to contact the firm regarding a class action lawsuit. The lawsuit alleges that Hims & Hers shared customers' protected health information with advertising platforms and engaged in deceptive advertising practices, including billing consumers immediately after intake forms and misrepresenting consultation availability. This conduct led to a significant stock drop after the Federal Trade Commission filed a lawsuit against the company.
Hims & Hers CFO Oluyemi Okupe sells $354,860 in stock
Hims & Hers Health, Inc. CFO Oluyemi Okupe sold 12,313 shares of the company's Class A Common Stock for $354,860 on September 17, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred while the stock was trading significantly below its 52-week high. The article also provides recent analyst ratings and company news, including the launch of GLP-1 medications in Australia and challenges related to customer credit card disputes.
Hims & Hers Health CFO Oluyemi Okupe Sells 12,313 Shares Under Rule 10b5-1 Plan
Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NYSE:HIMS), sold 12,313 Class A Common Stock shares at $28.82 each on September 17, 2026. This transaction was carried out under a Rule 10b5-1 trading plan adopted on May 20, 2026. Following the sale, Okupe directly holds 251,804 shares, with an additional 7,853 shares held indirectly through a trust.
Class-action lawsuit filed against Hims & Hers following FTC complaint
A class-action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. This lawsuit follows a Federal Trade Commission complaint alleging the company engaged in deceptive billing and unlawfully shared health data. Hims & Hers' shares plummeted 14.73% after the FTC's complaint became public.
Kaplan Fox & Kilsheimer LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm Before November 2, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit follows allegations by the FTC and other consumer protection agencies that Hims & Hers failed to disclose its practice of charging for prescriptions immediately, made it difficult to cancel subscriptions, and shared consumer health information with third parties. Investors who suffered losses are encouraged to contact Kaplan Fox before the November 2, 2026 deadline to potentially serve as a lead plaintiff.
INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - HIMS
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Hims & Hers Health, Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff. The lawsuit claims Hims & Hers shared consumer health information with third-party advertisers and engaged in deceptive billing practices, leading to a Federal Trade Commission lawsuit and a nearly 15% drop in stock price.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds purchasers of Hims & Hers Health, Inc. (NYSE: HIMS) securities during the period of August 4, 2025, to July 29, 2026, of the November 2, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Hims made misleading statements by failing to disclose that it shared consumer health information with third-party advertisers, charged for prescriptions before medical consultation, and was likely to face regulatory scrutiny and penalties. Investors who purchased HIMS securities during this period may be entitled to compensation and are encouraged to contact The Rosen Law Firm for more information.
Hims & Hers Health faces class action over alleged website tracking
Hims & Hers Health is facing a class action lawsuit alleging that the company used website tracking technologies to collect and disclose consumers' sensitive health information to third parties without consent. The lawsuit claims that Hims shared this data with companies like Amplitude, Meta, and Google to boost advertising revenue, violating privacy laws and the company's own privacy policy. This complaint comes while Hims is also dealing with a Federal Trade Commission lawsuit over alleged deceptive billing practices.
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit deadline of November 2, 2026, for investors who purchased Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers falsely claimed consumer privacy, deceptively charged for prescriptions, and engaged in other misleading advertising practices, leading to regulatory scrutiny from the Federal Trade Commission and a nearly 15% stock price decline. Investors suffering substantial losses are encouraged to seek lead plaintiff appointment.
HIMS & HERS HEALTH, INC. INVESTORS WITH LOSSES HAVE UNTIL NOVEMBER 2, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). Investors who purchased shares between August 4, 2025, and July 29, 2026, and suffered losses are encouraged to join by the November 2, 2026, deadline. The lawsuit alleges that the company made materially false and misleading statements about its business operations and financial stability, leading to artificially inflated stock prices.
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of Hims & Hers Health, Inc. that they have until November 2, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Hims & Hers Health, Inc. failed to disclose material information regarding deceptive privacy and billing practices, leading to a significant stock decline after the FTC filed a lawsuit against the company. Investors who purchased securities between August 4, 2025, and July 29, 2026, are encouraged to contact KSF for more information.
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has announced a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) for alleged deceptive privacy and billing practices. The lawsuit claims Hims failed to disclose material information, leading to a 14.73% stock decline following a Federal Trade Commission (FTC) lawsuit announcement. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to file lead plaintiff applications.
